Evaluation of a New Measure of Blood Glucose Variability in Diabetes

Diabetes Care - Tập 29 Số 11 - Trang 2433-2438 - 2006
Boris Kovatchev1, Erik Otto2, Daniel J. Cox1, Linda Gönder-Frederick1, William L. Clarke1
1University of Virginia Health System, Charlottesville, Virginia
2LifeScan, Milpitas, California

Tóm tắt

OBJECTIVE—Recent studies show the importance of controlling blood glucose variability in relationship to both reducing hypoglycemia and attenuating the risk for cardiovascular and behavioral complications due to hyperglycemia. It is therefore important to design variability measures that are equally predictive of low and high blood glucose excursions. RESEARCH DESIGN AND METHODS—We introduce the average daily risk range (ADRR), a variability measure computed from routine self-monitored blood glucose (SMBG) data. The ADRR was constructed using a development dataset for 39 and 31 adults with type 1 and type 2 diabetes, respectively. The formula was then fixed, and the ADRR was compared against other variability measures using an independent validation dataset containing ∼4 months of SMBG for 254 and 81 adults with type 1 and type 2 diabetes. RESULTS—From the 1st month of validation SMBG data, we computed the ADRR, blood glucose SD and coefficient of variation, daily blood glucose range and interquartile range, mean amplitude of glycemic excursion, M-value, and lability index. Then all measures were tested as predictors of low blood glucose (<2.2 mmol/l; <3.9 mmol/l) and high (>10 mmol/l; >22.2 mmol/l) events in the subsequent 3 months. The ADRR was the best predictor of both hypoglycemia and hyperglycemia, with a 6-fold increase in the likelihood of hypoglycemia and 3.5-fold increase in the likelihood of hyperglycemia across its risk categories. CONCLUSIONS—In a large SMBG database, the ADRR showed strong association with subsequent out-of-control glucose readings. Compared with other variability measures, the ADRR demonstrated a superior balance of sensitivity to predicting both hypoglycemia and hyperglycemia. This prediction was independent from type of diabetes.

Từ khóa


Tài liệu tham khảo

Aaby Svendsen P, Lauritzen T, Soegard U, Nerup J: Glycosylated haemoglobin and steady-state mean blood glucose concentration in type 1 (insulin-dependent) diabetes. Diabetologia 23: 403–405, 1982

Santiago JV: Lessons from the Diabetes Control and Complications Trial. Diabetes 42:1549–1554, 1993

UK Prospective Diabetes Study Group (UKPDS): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837–853, 1998

The Diabetes Control and Complications Trial Research Group: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968–983, 1995

The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271–286, 1997

Henderson JN, Allen KV, Deary IJ, Frier BM: Hypoglycemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 20:1016–1021, 2003

Cryer PE, Davis SN, Shamoon H: Hypoglycemia in diabetes. Diabetes Care 26:1902–1912, 2003

Cryer PE: Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 45:937–948, 2002

Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke WL: Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 21:1870–1875, 1998

Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke WL: Methods for quantifying self-monitoring blood glucose profiles exemplified by an examination of blood glucose patterns in patients with type 1 and type 2 diabetes. Diabetes Technol Ther 4:295–303, 2002

Kovatchev BP, Cox DJ, Kumar A, Gonder-Frederick LA, Clarke WL: Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose (SMBG) data. Diabetes Technol Ther 5:817–828, 2003

American Diabetes Association Workgroup on Hypoglycemia: Defining and reporting hypoglycemia in diabetes. Diabetes Care 28:1245–1249, 2005

American Diabetes Association: Postprandial blood glucose: consensus statement. Diabetes Care 24:775–778, 2001

Basu A, Alzaid A, Dinneen S, Caumo A, Cobelli C, Rizza R: Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest 97:2351–2361, 1996

Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234, 1998

Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577–1583, 1996

Hanefeld M: Post-prandial hyperglycaemia and vascular disease. Int J Clin Pract Suppl 13–18, 2000

Hanefeld M, Temelkova-Kurktschiev T: The postprandial state and the risk of atherosclerosis. Diabet Med 14(Suppl. 3):S6–S11, 1997

Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, Marra G, Tonutti L, Taboga C, Motz E: The role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 25:1439–1443, 2002

Ceriello A: New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes Care 26:1589–1596, 2003

Quagliaro L, Piconi L, Assalone R, Martinelli L, Motz E, Ceriello A: Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52:2795–2804, 2003

Esposito K, Giugliano D, Nappo F, Martella K, the Campanian Postprandial Hyperglycemia Study Group: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110:214–219, 2004

Laakso M: Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48:937–942, 1999

Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M: Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 23:1830–1834, 2000

Hirsch IB, Brownlee M: Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 19:178–181, 2005

Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke WL: Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care 20:1655–1658, 1997

Schlichtkrull J, Munck O, Jersild M: The M-value, an index of blood glucose control in diabetics. Acta Med Scand 177:95–102, 1965

Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, Shapiro AMJ, Vantyghem MC: Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation Diabetes 53:955–962, 2004

Service FJ, Molner GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF: Mean amplitude of glycemic excursions, a measure of diabetic instability Diabetes 19:644–655, 1970

Thông tin
Thông tin xuất bản

Diabetes Care

Tập 29 Số 11

2433-2438

Thông tin tác giả